Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3M Drug Delivery Systems

Foamix Pharmaceuticals Ltd.

Folia Biotech Inc.

Galderma S.A.

Idera Pharmaceuticals, Inc.

MedImmune, LLC

Merck & Co., Inc.

Resolve Therapeutics, LLC

VentiRx Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Toll Like Receptor 8 (CD288 or TLR8) Overview 7

Therapeutics Development 8

Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Stage of Development 8

Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Therapy Area 9

Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Indication 10

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Toll Like Receptor 8 (CD288 or TLR8) - Products under Development by Companies 14

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development 24

3M Drug Delivery Systems 24

Foamix Pharmaceuticals Ltd. 25

Folia Biotech Inc. 26

Galderma S.A. 27

Idera Pharmaceuticals, Inc. 28

MedImmune, LLC 29

Merck & Co., Inc. 30

Resolve Therapeutics, LLC 31

VentiRx Pharmaceuticals, Inc. 32

Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles 33

854-A - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Drug 1 to Agonize TLR7 and TLR8 for Oncology - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Drug 2 to Agonize TLR7 and TLR8 for Oncology - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Drug to Agonize TLR7 and TLR8 for Oncology - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

imiquimod - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

IMO-8400 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

IMO-9200 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

JB-6121 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

leishmaniasis vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

MEDI-9197 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

motolimod - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

resiquimod - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

RSLV-132 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VTX-1463 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VTX-294 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Projects 59

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products 60

Toll Like Receptor 8 (CD288 or TLR8) - Featured News & Press Releases 61

May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference 61

Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study 61

Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia 62

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 63

Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting 64

May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors 64

Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer 66

Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma 66

Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia 67

Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting 67

Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings 69

Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 70

Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy 70

Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 71

Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by 3M Drug Delivery Systems, H2 2016 24

Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 25

Pipeline by Folia Biotech Inc., H2 2016 26

Pipeline by Galderma S.A., H2 2016 27

Pipeline by Idera Pharmaceuticals, Inc., H2 2016 28

Pipeline by MedImmune, LLC, H2 2016 29

Pipeline by Merck & Co., Inc., H2 2016 30

Pipeline by Resolve Therapeutics, LLC, H2 2016 31

Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 32

Dormant Projects, H2 2016 59

Discontinued Products, H2 2016 60

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports